OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

OS Therapies, a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i Digital to enhance investor outreach. B2i Digital will implement data-driven strategies to raise awareness about OS Therapies’ pioneering research and upcoming milestones, including its potentially pivotal Phase 2b clinical trial for OST-HER2 in the rare pediatric orphan disease recurrent, resected metastatic osteosarcoma.

HealthTech Insights: Vizuro and DCB Join Forces to Revolutionize Drug Discovery and Precision Medicine with Causal Generative AI

“OS Therapies is an exceptional addition to our platform,” said David Shapiro, CEO of B2i Digital. “Their innovative cancer treatments, such as OST-HER2 for recurrent, resected metastatic osteosarcoma, hold significant potential to address unmet medical needs in oncology. We look forward to helping them share their progress and vision with the investment community.”

HealthTech Insights: Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

B2i Digital will highlight OS Therapies’ lead candidate, OST-HER2, an off-the-shelf immunotherapy designed to activate the immune system to target HER2-positive cancer cells. The Phase 2b trial for OST-HER2 in recurrent, resected metastatic osteosarcoma has completed enrollment and all patient visits, with the next clinical data update expected to be announced during the week of the JP Morgan Healthcare Conference 2025. Additionally, OS Therapies is advancing its tunable Antibody-Drug Conjugate (ADC) platform, which offers tailored cancer treatments with the potential of improved efficacy, and reduced side effects.

HealthTech Insights: Sun Knowledge Launches Advanced AI-powered Technology-Enabled Solutions to Boost Revenue Cycle Efficiency

“Our collaboration with B2i Digital aligns with our mission to bring life-changing treatments to patients and increase awareness of the unique therapeutic potential of our pipeline,” said Paul Romness, MHP, CEO of OS Therapies. “We are eager to engage with investors as we prepare for key milestones that could reshape how challenging cancers, especially metastatic disease, are addressed.”

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – einpresswire

Tags: Antibody-Drug Conjugate, B2i Digital, OS Therapies, OST-HER2

HealthTech Media Room

HealthTech Media Room is a leading B2B media publication platform providing in-depth coverage of the rapidly evolving healthcare technology and academic research sectors. Specializing in key focus areas such as MedTech, Pharma, Digital Health, Health IT, and Biotech, HealthTech Media Room delivers the latest news, trends, and insights across the entire HealthTech landscape. From breakthrough medical devices and innovative pharmaceuticals to cutting-edge digital health solutions, the platform highlights key players, strategic partnerships, and transformative technologies shaping the future of healthcare. Serving as a trusted resource for industry professionals, thought leaders, and healthcare organizations, HealthTech Media Room is dedicated to driving conversations and knowledge sharing in the global HealthTech community.